Waldencast plc Class A Ordinary Share (WALD) is a publicly traded Technology sector company. As of July 26, 2026, WALD trades at $1.69 with a market cap of $216.76M and a P/E ratio of 0.00. WALD moved -2.30% today. Year to date, WALD is -10.11%; over the trailing twelve months it is -29.88%. Its 52-week range spans $0.72 to $4.18. Analyst consensus is buy with an average price target of $2.50. Rallies surfaces WALD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Waldencast Gains FDA Nod for Obagi saypha ChIQ Filler for Cheek Augmentation: Waldencast received FDA approval for Obagi saypha ChIQ, a hyaluronic acid gel indicated for cheek augmentation and midface contour correction in adults over 21. This expands Obagi Medical’s injectable portfolio following strong feedback on saypha MagIQ, where 94% of injectors reported complementarity and 42.6% of practices began evaluating Obagi skincare.
| Metric | Value |
|---|---|
| Price | $1.69 |
| Market Cap | $216.76M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.18 |
| 52-Week Low | $0.72 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-14.43M |
| Gross Margin | 0.00% |
3 analysts cover WALD: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.50.